title: Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan.
abstract: Hepatitis C virus (HCV) infection has been associated with hepatic steatosis. However, the role of hepatic steatosis in the pathogenesis of HCV infection remains controversial. In our study, 425 consecutive HCV-viremic patients with biopsy-proven chronic hepatitis C (male, 264; mean age, 49.0 years) were enrolled. Scoring of hepatic steatosis was based on the method described by Kleiner and on histopathology performed using the Knodell and Scheuer systems. HCV RNA level and genotypes were determined at the time of biopsy. Hepatic steatosis was observed in 30.8% of patients, including 113 mild, 16 moderate, and 3 with severe hepatic steatosis. Patients with a body mass index (BMI) <23 kg/m(2) had a significantly lower rate (18.9%) of hepatic steatosis (P<0.001). Hepatic steatosis did not correlate with the hepatic necroinflammatory activity, but was related to hepatic fibrosis (P=0.035). Hepatic steatosis was also not associated with HCV RNA level, and the distribution was similar between patients with HCV genotype 1 and genotype 2 infection. According to multivariate analysis, BMI is the strongest risk factor associated with hepatic steatosis, followed by hepatic fibrosis and triglyceride level with odds ratios (95% confidence intervals) of 2.51 (1.49-4.23), 2.06 (1.14-3.70), and 1.02 (1.01-1.03), respectively. Hepatic steatosis was associated with being overweight, hepatic fibrosis, and triglyceride level in chronic hepatitis C.
authors.affiliation: Department of Occupational and Environmental Medicine, Kaohsiung Municipal HsiaoKang Hospital, Kaohsiung, Taiwan.
authors.forename: Meng-Hsuan
authors.initials: MH
authors.lastname: Hsieh
authors.forename: Li-Po
authors.initials: LP
authors.lastname: Lee
authors.forename: Ming-Yen
authors.initials: MY
authors.lastname: Hsieh
authors.forename: Kun-Bow
authors.initials: KB
authors.lastname: Tsai
authors.forename: Jee-Fu
authors.initials: JF
authors.lastname: Huang
authors.forename: Nai-Jen
authors.initials: NJ
authors.lastname: Hou
authors.forename: Shinn-Chern
authors.initials: SC
authors.lastname: Chen
authors.forename: Zu-Yau
authors.initials: ZY
authors.lastname: Lin
authors.forename: Ming-Yuh
authors.initials: MY
authors.lastname: Hsieh
authors.forename: Liang-Yen
authors.initials: LY
authors.lastname: Wang
authors.forename: Chia-Yen
authors.initials: CY
authors.lastname: Dai
authors.forename: Wan-Long
authors.initials: WL
authors.lastname: Chuang
authors.forename: Ming-Lung
authors.initials: ML
authors.lastname: Yu
mesh_terms: D000328:Adult; D000367:Age Factors; D001706:Biopsy; D015992:Body Mass Index; D005234:Fatty Liver / Q000150:complications* / Q000473:pathology; D005260:Female; D016174:Hepacivirus / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000473:pathology / Q000821:virology; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013624:Taiwan; D014280:Triglycerides / Q000097:blood
chemical_list: D014280:Triglycerides